Navigation Links
Proacta Incorporated and Yakult Honsha Announce an Agreement for the Collaborative Research, Development and Commercialization for Proacta's PR509 Compound
Date:2/22/2011

nd Cancer Society Research Centre, University of Auckland, New Zealand.  Reversible multi-kinase inhibitors (MKI) are currently in use for the treatment of several types of cancer.  However, resistance often develops to reversible MKI's.  In addition, reversible MKI's have side effects that limit the use of higher doses.  PR509 utilizes an irreversible MKI that is activated only in areas of severe hypoxia, a characteristic of most solid tumors.  Localized release of the irreversible MKI leads to higher concentrations in the tumor relative to normal tissues, which should result in improved efficacy and fewer side effects.  In addition, irreversible MKI inhibitors are not subject to some of the resistance mechanisms applicable to reversible MKI inhibitors.

Clinical Development Status

PR509 is currently targeted for development in non-small cell lung cancer resistant to reversible tyrosine kinase inhibitors such as erlotinib and /or gefitinib, where an effective treatment has yet to be established.  In addition to NSCLC, Proacta expects to evaluate PR509 in other cancers such as gastric, breast, and pancreatic that are currently treated with first-generation reversible tyrosine kinase inhibitors.

About Proacta Incorporated

Proacta is a San Diego based biotechnology company dedicated to the development and commercialization of hypoxia-activated oncology drugs. Proacta is currently conducting a phase II study of PR104, a hypoxia activated alkylator, in patients with relapsed or refractory leukemia.  In addition, Proacta has a pipeline of hypoxia-activated prodrugs for the treatment of cancer that are licensed from the University of Auckland in New Zealand.  For more information on Proacta, visit the Proacta web site at www.proacta.com.

About Yakult

Yakult is a leading Japanese company focused on the development and marketing of pharmaceuticals, foo
'/>"/>

SOURCE Proacta Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DJO Incorporated Completes Business Integration and Changes Name to DJO Global, Inc.
2. DJO Incorporated Announces Planned Transition of President and CEO Les Cross
3. DJO Incorporated Acquires Manufacturer of Compression Therapy Products, Elastic Therapy, Inc.
4. Accuray Incorporateds CEO to Speak at 29th Annual J.P. Morgan Healthcare Conference
5. NASDAQ Grants Insmed Incorporated 180-Day Extension to Regain Compliance with Minimum Bid Price Rule
6. Accuray Incorporated to Speak at Oppenheimers 21st Annual Healthcare Conference
7. Accuray Incorporated to Report Financial Results for First Quarter of Fiscal 2011
8. Accuray Incorporated to Host Analyst Meeting at ASTRO 2010
9. Accuray Incorporated to Speak at JMP Securities Healthcare Conference
10. Accuray Incorporateds CEO to Speak at UBS Global Life Sciences Conference
11. Havels Incorporated Helping to Reduce Radiation Exposure with New EchoTuohy™ Ultrasound Needle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- The Physician-Patient Alliance for Health & Safety ... "Surviving Your Hospital Stay: Physician-Patient Alliance for Health ... A sentence was omitted from the release. ... is a member of the National Coalition to Promote ... the National Coalition to Promote Continuous Monitoring of Patients ...
(Date:7/31/2015)... LONDON , July 31, 2015 ... to decades of experience, the domestic pharmaceutical industry is ... today manufacture products to high international standards. ... well known is in sub-Saharan Africa: Morocco has quietly ... after South Africa . Indeed, Moroccan ...
(Date:7/31/2015)... Calif. , July 31, 2015  Xencor, Inc. ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... appointment of Yujiro S. Hata to its ... experience in business and corporate development is a tremendous ... Ph.D., president and chief executive officer of Xencor. "Xencor ...
Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... Final results from,a 24-week study presented today at ... olanzapine long-acting injection (LAI),therapeutic doses showed a maintenance ... review of pooled safety data from all olanzapine ... Olanzapine LAI is an investigational formulation that ...
... 2 Debiopharm Group,(Debiopharm), a global independent ... and particularly oncology, today,announced the signature of ... de Lausanne (EPFL), aimed at the identification ... with pathways controlling cell fate,specification. The project, ...
Cached Medicine Technology:Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 2Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 3Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 4Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 5Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 6Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 7Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 8Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 9Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment 2
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured on NewsWatch as ... applications on the market for iOS, Android, and Windows. Joe Toohey, the host of ... to clarify, edit and delete any message including ones already sent. , While text ...
(Date:7/31/2015)... ... , ... The Honor Society of Nursing, Sigma Theta Tau International (STTI) convened ... 20-21 July 2015 in San Juan, Puerto Rico. Key nurse leaders from Central and ... Advisor, Nursing and Allied Health Personnel Development, Unit of Human Resources for Health, Department ...
(Date:7/31/2015)... ... July 31, 2015 , ... Last week, ... GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store . , “Our ... customizable. The best part: whenever a product is purchased, the Meso Foundation receives ...
(Date:7/31/2015)... Rolling Meadows, IL (PRWEB) , ... July 31, ... ... great ways to communicate. Rally Insurance Group, Inc. has re-branded their social media ... provides a personal way for consumers to communicate, find information, share insights ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to an article published July ... they could reach a consensus on the steps that need to be taken to ... reached 90 percent consensus on a series of steps that each surgeon must complete ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... ... refusing travellers with symptoms similar to flu to board planes, travel insurers are treating swine ... ... AA Travel Insurance are now enquiries from travellers concerned about whether they are covered if ...
... who struggle with CPAP treatment for obstructive sleep apnea ... the upper airway, because it holds the same quality-of-life ... in new research published in the August 2009 edition ... positive airway pressure (CPAP) therapy is a highly effective ...
... Speaker Nancy Pelosi issued the following statement tonight on the vote ... Affordable Health Choices Act, the third House committee to pass the ... Education and Labor Committee approved the bill earlier this month: ... have tried as a nation to make quality, affordable health insurance ...
... for people living with AIDS and increases with increasing ... 31 in the Journal of the National Cancer ... is known to be higher among people with AIDS, ... is unclear. Anil K. Chaturvedi, Ph.D., of the ...
... , NEW YORK, July 31 BBV Vietnam ... "Company") announced today that it has signed a non-binding letter of ... Pursuant to the provisions of the Company,s Articles of Incorporation, the ... combination. If the Company is unable to complete the business combination ...
... more health and social issues years later , FRIDAY, July ... neuroblastoma face long-term health and social problems, according to a ... who had been diagnosed with neuroblastoma -- a cancer that ... comparing it with data on 3,899 siblings of children with ...
Cached Medicine News:Health News:Play it Straight with Swine Flu, AA Travel Insurance Advises 2Health News:Play it Straight with Swine Flu, AA Travel Insurance Advises 3Health News:Play it Straight with Swine Flu, AA Travel Insurance Advises 4Health News:AIDS patients face higher risk of HPV-related cancers as immunosuppression grows 2Health News:BBV Vietnam S.E.A. Acquisition Corp. Announces Signing of Letter of Intent for Business Combination with Migami, Inc. 2
... Launched in 1996, VISIPAQUE is the only isosmolar ... an osmolality equal to that of blood, VISIPAQUE ... is also the only contrast medium formulated with ... blood. In 1997, VISIPAQUE received FDA approval for ...
The Mitek Restore System, designed in conjunction with Sanford S. Kunkel, M.D., offers instrumentation for all ACL Procedures....
Hand surgery basic instrument set...
Castroviejo caliper...
Medicine Products: